Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27431819 | 0.84 | SMN1; SMN2 (0.54) | RAB9ANPC1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL13295865 | 0.84 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL7623974 | 0.83 | KMT2A (0.69) | RAB9ANPC1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL11752289 | 0.83 | KMT2A (0.74) | RAB9ANPC1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL7618750 | 0.82 | NPC1 (0.53) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL2273935 | 0.81 | PRSS1 (0.56) | RAB9ANPC1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL14120823 | 0.81 | POLB (0.62) | RAB9ANPC1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL27335124 | 0.80 | PRSS1 (0.54) | RAB9ANPC1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL863105 | 0.80 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL2667533 | 0.80 | LMNA (0.56) | RAB9ANPC1SMN1; SMN2KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020061839-A1 | Serine peptidase modulators | SCHARPE SIMON LODEWIJK (BE) | 2002-05-23 | — | — | US | disclosed |
| EP-1062222-A1 | SERINE PEPTIDASE MODULATORS | Fondatech Benelux N.V. (BE) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046272-A1 | SERINE PEPTIDASE MODULATORS | FONDATECH BENELUX N.V. (BE) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061839-A1 | Serine peptidase modulators | FAP, CTSC, DPP4 | RAB9A 1859/4885NPC1 1311/4885SMN1; SMN2 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.